论文部分内容阅读
目的探讨甲强龙对重症支气管哮喘患者的治疗效果。方法 80例重症支气管哮喘患者被随机分为治疗组和对照组,在常规基本治疗的基础上,治疗组加用甲强龙,对照组加用地塞米松。结果治疗组40例患者,症状及体征缓解率为93.2%;对照组40例患者中,症状及体征缓解率为68.9%,两组缓解率相比,差异具有统计学意义(p<0.05);两组患者在治疗之前各项血气指标的差异没有统计学意义(p>0.05);治疗后,两组患者的PaO2和PaCO2均有了明显的改善,但治疗组的改善更为明显,两组之间差异显著,具有统计学意义(p<0.05)。结论甲强龙对于重症支气管哮喘患者有较好的疗效,值得临床进一步推广。
Objective To investigate the therapeutic effect of methylprednisolone on patients with severe bronchial asthma. Methods Eighty patients with severe bronchial asthma were randomly divided into treatment group and control group. On the basis of routine basic treatment, the treatment group received methylprednisolone and the control group received dexamethasone. Results The response rate and symptom relief rate of the 40 patients in the treatment group was 93.2%. In 40 patients in the control group, the symptom and symptom relief rate was 68.9%. The difference was statistically significant (p <0.05). Before treatment, there was no significant difference of blood gas indexes between the two groups (p> 0.05). After treatment, the PaO2 and PaCO2 in both groups were significantly improved, but the improvement in the treatment group was more obvious. The two groups The difference was significant, with statistical significance (p <0.05). Conclusion Metronidazole for patients with severe bronchial asthma has a good effect, it is worth further clinical promotion.